Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01267292 · ClinicalTrials.gov registry record · Phase 2
Psychopharmacology for Cocaine Dependence - Buspirone
A Phase 2 study, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT01267292 is a Phase 2 study that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 50 participants.
The verdict
NCT01267292, a Phase 2 study, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
Chronic cocaine use may produce disruption of neurotransmitter functions (including dopamine). This may in turn contribute to measurable dysfunction in important cognitive and behavioral processes. Stimulants that enhance dopamine (DA) function may help in treating cocaine dependence and improving behavioral function -- supporting the notion that these processes are related. An important step is to understand the subjective, physiological, and behavioral effects of potential medications for cocaine dependence. DA-modulating drugs may be targets for pharmacotherapy for substance dependence, and particularly for stimulant drugs like cocaine, which disrupt normal DA function. Buspirone is currently the only available dopamine subtype 3 (DA3) approved for human administration, and is thus a viable investigational compound. This project proposes to evaluate the DA-modulating effects of buspirone on behavioral deficiencies related to DA depletion. Accordingly, the project aims to characterize the effects of buspirone in individuals with cocaine dependence. Employing a daily dosing designs within an acute stimulant challenge (methylphenidate), the experiment will characterize the subjective effects, cardiovascular effects, and behavioral effects (attentional bias to drug cues and risky decision making). The primary hypotheses are that buspirone will attenuate the increases in subjective drug effects ("stimulated", "like drug") and behavioral effects (increases in attentional bias and risky decision making) that are produced by acute methylphenidate administration.
Interventions
- DRUG Methylphenidate
- DRUG Buspirone
- DRUG Placebo for Buspirone
- DRUG Placebo for Methylphenidate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2011-03 |
| Est. Completion | 2015-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01267292
The ClinicalTrials.gov registry entry for NCT01267292 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Methylphenidate is the first listed.
NCT01267292 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01267292 about?
NCT01267292 is a clinical study titled "Psychopharmacology for Cocaine Dependence - Buspirone". Chronic cocaine use may produce disruption of neurotransmitter functions (including dopamine). This may in turn contribute to measurable dysfunction in important cognitive and behavioral processes. Stimulants that enhance dopamine (DA) function may help in treating cocaine dependence and improving b...
What is the current status of trial NCT01267292?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2011-03. Estimated completion is 2015-12.
What interventions are being tested in trial NCT01267292?
The interventions under investigation include: Methylphenidate (DRUG), Buspirone (DRUG), Placebo for Buspirone (DRUG), Placebo for Methylphenidate (DRUG).
Who is sponsoring clinical trial NCT01267292?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.